Welcome international healthcare professionals

This site is no longer supported and will not be updated with new content. You are welcome to browse and download all content already included in the site. Please note you will have to register your email address to access the site.

You are here

Insights in Hodgkin Lymphoma angiogenesis

Leukemia Research, 8, 38, pages 857 - 861

Highlights

 

  • Angiogenesis is a hallmark of tumor growth and progression in malignancies.
  • Data concerning the angiogenesis of HL are limited if compared with non-HL.
  • Studies of angiogenesis inhibitors demonstrated antitumor effects in HL.

Abstract

Angiogenesis is a hallmark of tumor growth and progression in solid and hematological malignancies. Different cellular components of the tumor microenvironment such as macrophages, mast cells, circulating endothelial cells and angiogenic factors, including vascular endothelial growth factor and its receptors are involved in the maintenance of Hodgkin Lymphoma. In this review article, we highlight relevant literature focusing on the relationships between angiogenesis and Hodgkin Lymphoma as well as discussing anti-angiogenic treatments in this malignancy.

Keywords: Angiogenesis, Anti-angiogenesis, Hodgkin Lymphoma, Tumor microenvironment.

1. Introduction

Angiogenesis is recognized as the process of formation of new blood vessels from pre-existing ones. This process occurs both in physiological conditions such as embryonic development and ovulation, and in pathologic conditions such as wound healing and cancer. The development of a tumor follows two main phases, the first known as the avascular phase, in which tumor growth is limited by the availability of nutrients and oxygen provided by blood vessels, the second known as the vascular phase, in which the tumor cell acquire an angiogenic phenotype to promote the formation of new blood vessels that can support tumor growth [1] . The angiogenic switch that governs the transition from one phase to the another is mediated by a shift in the balance of pro-angiogenic and anti-angiogenic factors by increased gene expression, changing of the bioavailability or activity of the pro-angiogenic molecules, or reduced concentration of anti-angiogenic mediators. The progression of solid tumors and hematological malignancies is clearly related to their degree of angiogenesis [1] . Lymphomas constitute a large group of lympho-proliferative disorders classified on the basis of morphologic, immunologic, genetic, and clinical criteria. Hodgkin Lymphomas (HL) display distinct morphological hallmarks described for the first time over 100 years ago. They are characterized by mono- and multi-nucleated Hodgkin–Reed–Stenberg (HRS) cells in classical Hodgkin Lymphoma (cHL) which encompasses mixed cellularity, nodular sclerosis and lymphocyte rich subtypes, and accounts for approximately 95% of HL cases, and lymphocyte predominant (LP) cells in nodular lymphocyte-predominant HL (NLPHL), which represent only 5% of HL cases [2] .

Introduction of modern radiotherapy and polychemotherapy in 1960s and 1970s has significantly reduced the number of deaths associated to HL, with the consequent development of modern treatment strategies based on the distinction between cHL and NLPHL and only limited study of new treatments for advanced disease [3] . However, treatment failure persists in a substantial proportion of patients, underscoring the need of novel biomarkers and new therapeutic approaches to treat non-responding and relapsed HL. The growing importance of the tumor microenvironment and its cellular and molecular components might be an important target in developing such novel strategies.

In this review article we will focus on the relationship between angiogenesis in the context of the tumor microenvironment and disease progression in human HL.

2. In vitro and in vivo experimental models

Expression of angiogenic factors by lymphoid tumor cells was reported in several studies involving both in vitro and in vivo experimental models. Vascular endothelial growth factor (VEGF) is expressed by HRS cell lines L428 and KM-H2 in conditions of normoxia and hypoxia as demonstrated by FACS analysis and immunoassay of cell culture supernatant, indicating the potential role of HRS cells in enhancing angiogenesis by the secretion of a strong mitogen for endothelial cells as VEGF [4] . Gharbaran et al. [5] reported an overexpression of fibroblast growth factor-2 (FGF-2) and syndecan-1 (SDC-1) in ten HL cell lines and confirmed their increased expression in poor outcome and good outcome groups of HL patients by quantitative RT-PCR.

Notably, there is no report available about the evaluation of the angiogenic potential of HL cells with in vivo models such as the chick embryo chorioallantoic membrane (CAM). Xenotransplantation in NOD/SCID mouse strain has been evaluated for several myeloid and lymphoid tumor cell lines [6], [7], and [8], while increased tumor vascularity was observed when HL cell lines KMH2, L428 and HDLM2 were injected in conjunction with bone marrow mast cells in NOD/SCID mouse [9] .

3. Angiogenesis in HL

There are no literature data concerning the morphological and ultrastructural features of tumor vessels in HL.

Korkolopoulou et al. [10] investigated angiogenesis in 286 HL patients using a morphometric approach. Parameters of the vessels such as caliber showed a gradual increase through Ann Arbor stages I–IV supporting the notion that the larger the lumen of the microvessel the higher the chance of neoplastic cells to have access into the circulation. Conversely, microvascular density (MVD) declined with stage progression. The disparity between these parameters may be a consequence of the prevalence of vessels differentiating factors upon vascular growth factors. Moreover, a prognostic relevance of the morphometric variables was established through multivariate analysis [10] .

Several studies investigated the expression of angiogenic cytokines in biopsy specimens of different HL subtypes. VEGF, matrix metalloproteinases-2 and -9 (MMP-2 and MMP-9) and tissue inhibitor of MMP-1 (TIMP1) are expressed in HRS cells in childhood HL. MMP-9 was significantly correlated with B symptoms while TIMP-1 in reactive lymphocytes correlated with advanced stage. However MVD was not correlated with expression of this cytokines in HRS cells [11] . Kuittinen et al. [12] also found a correlation between MMP-9 in reactive lymphocytes and B symptoms but no correlation between extent of neovascularization and level MMP-2 expression in malignant cells or reactive lymphocytes. Expression of hepatocyte growth factor (HGF) and its receptor c-met was found respectively in the reactive cellular background and in HRS cells from HL biopsy specimens [13] but there is no report of its correlation with potential stimulation of the angiogenic response by this cytokine in HL. Hypoxia Inducible Factor 1 alpha (HIF-1α) was investigated as well by immunohistochemistry in HL and found to be expressed moderately in the nuclei of HRS cells but not correlated with increased MVD suggesting that HL may utilize other angiogenic pathways relatively independent from HIF-1α [14] . Expression of VEGF-D was also evaluated by immunohistochemistry both in non-HL (NHL) and HL and found to be strongly expressed by HRS cells in line with a high number of tumor microvessels suggesting a role for this cytokine in angiogenesis [15] . Khnykin et al. [16] studied the FGF cytokines family and their receptors in HRS cells both at the protein and gene expression levels, but again no direct relationship was established between the expression of these cytokines and neovascularization.

Relevance of circulating serum levels of angiogenic factors has been demonstrated in several studies. In a retrospective study involving 67 patients of NHL and 37 patients of HL pre-treatment serum levels of VEGF, FGF-2, HGF and angiogenin were measured and compared to post-therapy levels. Patients with HD had abnormally elevated pre-treatment VEGF and HGF levels which were significantly reduced post-therapy and notably both pre-therapy and post-therapy VEGF levels were predictive of survival [17] . Elevated VEGF serum levels present in pre-treatment HL patients undergo a reduction in patients with prolonged complete remission, but these levels are still elevated when compared to healthy subjects’ serum VEGF levels [18] . The post-treatment reduction of VEGF serum levels was also observed in a group of 36 patients with pediatric lymphomas in addition to a significant increase of post-treatment serum endostatin in the same cohort of patients [19] . These studies further support a role of angiogenesis in hematological malignancies in which the net balance of angiogenic and anti-angiogenic stimulus is shifted toward the angiogenic phenotype.

Vascular endothelial growth factor receptor-1 (VEGFR-1) and VEGFR-2 are two highly related tyrosine kinase receptors that bind VEGF-A and promote survival of endothelial cells through the Raf-MEK-MAP kinase pathway [20] and [21]. Dimtsas et al. [22] evaluated the expression pattern of VEGF-A, VEGFR-1 and VEGFR-2 retrospectively in cHL and NLPHL for a total of 194 cases and found these angiogenic cytokines were expressed in the majority of the cases by HRS cells and lymphocytic and histiocytic cells. Moreover, a significant correlation between these markers and vessel branching was observed while no correlation was found between other microvascular parameters and the expression of these angiogenic markers.

4. Macrophages and mast cells in HL angiogenesis

Inflammatory infiltrate in tumors consists of different types of cells capable of supporting tumor growth and neovascularization by the production of several angiogenic factors. Tumor associated macrophages have been studied and correlated to clinical outcome and clinic-pathological features of HL with various results [23], [24], and [25]. Immunohistochemistry studies involved mainly CD68 as a marker for tumor associated macrophages ( Fig. 1 A) but CD163 was found to be superior in predicting outcome in HL [26] .

gr1

Fig. 1 Immunohistochemical pictures of macrophages stained with an antibody anti-CD68 (in A) and mast cells stained with an antibody anti-tryptase (in B) in the stroma of human HL specimens. Original magnification: 160×.

CD163 expression was correlated with angiogenesis in uniformly treated classical HL. A significant correlation between MVD and expression of CD163 and VEGF suggest an interaction between HRS cells and tumor associated macrophages that leads to increased angiogenesis and poor clinical outcome [27] .

Mast cells infiltration ( Fig. 1 B) correlates with poor prognosis in HL [28] with a proposed mechanism involving the stimulation of HRS by CD30L produced by mast cells. The extent of angiogenesis in relation to mast cells count has been studied, but no significant correlation was found between high microvessel count and high number of mast cells [29] . However, the contribution of mast cells to tumor growth of HL cell lines in vivo was tested revealing that tumors derived from inoculation of HL cells and mast cells possessed increased vasculature when compared with tumors derived from HL cell inoculation alone [9] .

5. Circulating endothelial progenitor cells and circulating endothelial cells

Circulating endothelial progenitor cells (CEPCs) are present within the blood flow during tumor development and evidence indicates a potential role for the bone marrow derived CEPCs in tumor angiogenesis [30] . Although CEPCs levels in response to treatment have been studied in indolent and aggressive NHL [31] and the increase of CD34+CD133+ CEPCs was correlated to the stage of NHL by means of flow cytometry [32] no report is available on the CEPCs and their relevance in the progression of the tumor angiogenesis in HL.

6. Antiangiogenic therapy in HL

The concept of targeting tumor blood vessels, a source of support for tumor growth, is a promising therapeutic approach in cancer. This section will focus on pre-clinical and clinical studies of various angiogenesis inhibitors which demonstrated some antitumor effects mainly in relapsed and refractory HL.

6.1. Immunomodulatory drugs

Thalidomide has been demonstrated to have anti-angiogenic activity through inhibition of cytokines such as tumor necrosis factor-α and VEGF [33] . Several reports evaluated the response rate of thalidomide in combination with cyclophosphamide and dexamethasone [34] and vinblastine [35] in relapsed HL demonstrating good clinical activity of thalidomide in combined therapeutic regimens in small populations of patients.

Lenalidomide is a potent analog of thalidomide, with diverse mechanisms of action not fully understood such as induction of apoptosis in tumor cells, anti-angiogenic effects and modulation of immune cells such as T and NK cells [36] and [37].

The clinical activity of lenalidomide alone was investigated in a cohort of 38 patients with heavily pretreated refractory or relapsed cHL demonstrating objective and cytostatic responses in the patient population with modest toxicity. The clinical response achieved in cHL may be indirect and referred to the tumor microenvironment as lenalidomide failed to kill or arrest growth of cHL cell lines in vitro, but the lack of spontaneous mouse models of cHL render difficult the investigation of the indirect mechanisms of lenalidomide in vivo [38] . Boll et al. [39] achieved 50% responses in 12 patients treated with lenalidomide outside a clinical trial observing low toxicity as well.

Moreover, lenalidomide has also been used in combination with etoposide, cytarabine, cisplatin and methylprednisolone (ESHAP) chemotherapy in three patients with relapsing disease after autologous stem cell transplantation resulting in complete isotopic remission evaluated by 18-fluoro-2-deoxy-glucose positron emission tomography (18F-FDG PET) [40] .

Proteasome inhibitors such as bortezomib, inhibit cancer growth through down-regulation of NF-Kb, a transcription factor involved in the synthesis of anti-apoptotic and angiogenic factors [41] . Bortezomib was evaluated as a single agent in relapsed/refractory cHL but resulted in a weak or absent clinical activity with mainly progressive disease in the patient population studied [42] and [43] calling for further investigations of the activity of this inhibitor in combination therapy.

6.2. Anti-VEGF monoclonal antibodies and VEGFR inhibitors

The neoplastic cell influences the contextual micro-environment to support tumor growth and progression through production of various molecules acting on different receptors. Tyrosine kinase receptors and their ligands mediate the activation of a variety of cellular pathways involved in cancer. The VEGF/VEGFR pathway has a key role in the regulation of angiogenesis making its inhibition a target for therapeutic agents in preclinical and clinical studies.

The effects of bevacizumab, an anti-VEGF monoclonal antibody, were investigated against human HL xenografts in SCID mouse and in five patients with refractory/relapsed HL. A significant delay in the growth of HL tumors was observed in the animal model, while the clinical activity of bevacizumab as a single agent or in combination with gemcitabine resulted in biological activity and partial or complete remission in 3 of 5 patients respectively [44] .

Although VEGFR expression was investigated but not considered as a prognostic factor in cHL [22] , no clinical report is available concerning the activity of VEGFR inhibitors in refractory/relapsing HL.

6.3. Histone deacetylase inhibitors

Epigenetic modifications have been shown to affect tumor development through the regulation of gene expression without changes in the DNA sequence itself. Acetylation and deacetylation of histone protein influence chromatin accessibility to the transcription machinery thus modifying gene expression. Inhibition of histone deacetylases (HDACs) causes the reversion of the malignant phenotype of cancer cells making it an interesting therapeutic approach [45] .

Vorinostat and panobinostat have been evaluated in refractory/relapsed HL [46], [47], and [48]. Furthermore, panobinostat at the molecular level inhibited two members of the STAT transcription factors family (STAT5 and STAT6) and downregulated HIF-1α and its downstream targets glucose transporter 1 (GLUT-1) and VEGF in HL cell lines [49] , suggesting a role in the inhibition of the angiogenic process through the reduced level of VEGF secreted by HL cells.

7. Concluding remarks

The importance of angiogenesis as a hallmark of tumor development is well recognized both in solid tumors and hematological malignancies such as lymphoma. Literature data concerning the angiogenesis of HL is limited if compared with NHL, with most of the studies performed by retrospective immunohistochemical analysis, where evidence of correlation between cellular components of the microenvironment and increased vascularity has been established.

Antiangiogenic therapy as monotherapy seems to have minimal responses on relapsed and refractory patients and better clinical activity when used in combination therapy with generally low toxicity.

Further research should employ in vitro and in vivo models to better elucidate the interactions of HRS cells, tumor microenvironment and tumor vascularity as well as investigating new therapeutic approaches for patients with relapsed or refractory disease.

Conflict of interest statement

The authors declare no conflict of interest.

Acknowledgment

This work has been supported by the Association against lymphomas “Il Sorriso di Antonio”, Corato, Italy.

References

  • [1] D. Ribatti, B. Nico, E. Crivellato, A.M. Roccaro, A. Vacca. The history of the angiogenic switch concept. Leukemia. 2007;21:44-52 Crossref
  • [2] S. Swerdlow, E. Campo, N. Harris, E. Jaffe, S. Pileri, H. Stein, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. (International Agency for Research on Cancer, Lyon, France, 2008)
  • [3] C. Steidl, J.M. Connors, R.D. Gascoyne. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29:1812-1826 Crossref
  • [4] I.A. Doussis-Anagnostopoulou, K.L. Talks, H. Turley, P. Debnam, D.C. Tan, G. Mariatos, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin–Reed–Sternberg cells in Hodgkin's disease. J Pathol. 2002;197:677-683 Crossref
  • [5] R. Gharbaran, A. Goy, T. Tanaka, J. Park, C. Kim, N. Hasan, et al. Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients. J Hematol Oncol. 2013;6:62 Crossref
  • [6] M.Z. Dewan, M. Watanabe, S. Ahmed, K. Terashima, S. Horiuchi, T. Sata, et al. Hodgkin's lymphoma cells are efficiently engrafted and tumor marker CD30 is expressed with constitutive nuclear factor-kappaB activity in unconditioned NOD/SCID/gammac(null) mice. Cancer Sci. 2005;96:466-473 Crossref
  • [7] A. Di Stasi, B. De Angelis, C.M. Rooney, L. Zhang, A. Mahendravada, A.E. Foster, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113:6392-6402 Crossref
  • [8] L. Fusetti, G. Pruneri, A. Gobbi, C. Rabascio, N. Carboni, F. Peccatori, et al. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. Cancer Res. 2000;60:2527-2534
  • [9] H. Mizuno, T. Nakayama, Y. Miyata, S. Saito, S. Nishiwaki, N. Nakao, et al. Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib. Leukemia. 2012;26:2269-2276 Crossref
  • [10] P. Korkolopoulou, I. Thymara, N. Kavantzas, T.P. Vassilakopoulos, M.K. Angelopoulou, S.I. Kokoris, et al. Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia. 2005;19:894-900 Crossref
  • [11] E.C. Citak, A. Oguz, C. Karadeniz, N. Akyurek. Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma. Pathol Res Pract. 2008;204:89-96 Crossref
  • [12] O. Kuittinen, Y. Soini, T. Turpeenniemi-Hujanen. Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma. Eur J Haematol. 2002;69:205-212 Crossref
  • [13] L. Teofili, A.L. Di Febo, F. Pierconti, N. Maggiano, M. Bendandi, S. Rutella, et al. Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood. 2001;97:1063-1069 Crossref
  • [14] F.H. Passam, M.G. Alexandrakis, M. Kafousi, M. Fotinou, K. Darivianaki, G. Tsirakis, et al. Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma. Pathol Res Pract. 2009;205:11-20 Crossref
  • [15] M. Bardelli, E. Leucci, K. Schurfeld, C. Bellan, G. Passiatore, M. Rocchigiani, et al. VEGF-D is expressed in activated lymphoid cells and in tumors of hematopoietic and lymphoid tissues. Leuk Lymphoma. 2007;48:2014-2021 Crossref
  • [16] D. Khnykin, G. Troen, J.M. Berner, J. Delabie. The expression of fibroblast growth factors and their receptors in Hodgkin's lymphoma. J Pathol. 2006;208:431-438 Crossref
  • [17] F.J. Giles, J.M. Vose, K.A. Do, M.M. Johnson, T. Manshouri, G. Bociek, et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res. 2004;28:595-604 Crossref
  • [18] A. Rueda, D. Olmos, V. Villareal, E. Torres, B.I. Pajares, E. Alba. Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission. Clin Lymphoma Myeloma. 2007;7:400-405 Crossref
  • [19] F.V. Okur, C. Karadeniz, M. Buyukpamukcu, A. Oguz, A. Yucel, P. Cinaz, et al. Clinical significance of serum vascular endothelial growth factor, endostatin, and leptin levels in children with lymphoma. Pediatr Blood Cancer. 2010;55:1272-1277 Crossref
  • [20] H. Gille, J. Kowalski, B. Li, J. LeCouter, B. Moffat, T.F. Zioncheck, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem. 2001;276:3222-3230 Crossref
  • [21] T. Takahashi, S. Yamaguchi, K. Chida, M. Shibuya. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J. 2001;20:2768-2778 Crossref
  • [22] G.S. Dimtsas, E.C. Georgiadi, P. Karakitsos, T.P. Vassilakopoulos, I. Thymara, P. Korkolopoulou, et al. Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma. Leuk Lymphoma. 2014;55:558-564 Crossref
  • [23] D. Azambuja, Y. Natkunam, I. Biasoli, I.S. Lossos, M.W. Anderson, J.C. Morais, et al. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol. 2012;23:736-742 Crossref
  • [24] S. Kayal, S. Mathur, A.K. Karak, L. Kumar, A. Sharma, S. Bakhshi, et al. CD68 tumor-associated macrophage marker is not prognostic of clinical outcome in classical Hodgkin lymphoma. Leuk Lymphoma. 2014;55:1031-1037 Crossref
  • [25] B. Sanchez-Espiridion, A.M. Martin-Moreno, C. Montalban, L.J. Medeiros, F. Vega, A. Younes, et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica. 2012;97:1080-1084 Crossref
  • [26] J.L. Klein, T.T. Nguyen, G.A. Bien-Willner, L. Chen, K.V. Foyil, N.L. Bartlett, et al. CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma. Am J Clin Pathol. 2014;141:381-387 Crossref
  • [27] Y.W. Koh, C.S. Park, D.H. Yoon, C. Suh, J. Huh. CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma. PLOS ONE. 2014;9:e87066 Crossref
  • [28] D. Molin, A. Edstrom, I. Glimelius, B. Glimelius, G. Nilsson, C. Sundstrom, et al. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol. 2002;119:122-124 Crossref
  • [29] I. Glimelius, A. Edstrom, M. Fischer, G. Nilsson, C. Sundstrom, D. Molin, et al. Angiogenesis and mast cells in Hodgkin lymphoma. Leukemia. 2005;19:2360-2362
  • [30] D. Ribatti. The discovery of endothelial progenitor cells. An historical review. Leuk Res. 2007;31:439-444 Crossref
  • [31] D. Ribatti, B. Nico, G. Ranieri, G. Specchia, A. Vacca. The role of angiogenesis in human non-Hodgkin lymphomas. Neoplasia. 2013;15:231-238
  • [32] D.D. Yu, H.L. Liu, Y.L. Bai, B. Wu, W.H. Chen, J.H. Ren, et al. Correlation between increased circulating endothelial progenitor cells and stage of non-Hodgkin lymphoma. J Huazhong Univ Sci Technol Med Sci. 2013;33:284-287 Crossref
  • [33] D. Ribatti, A. Vacca. Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. Leukemia. 2005;19:1525-1531 Crossref
  • [34] R. Garcia-Sanz, T.J. Gonzalez-Lopez, L. Vazquez, G. Hermida, I.F. Graciani, J.F. San Miguel. The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma. Eur J Haematol. 2010;84:266-270 Crossref
  • [35] J. Kuruvilla, K. Song, P. Mollee, T. Panzarella, J. McCrae, T. Nagy, et al. A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology. 2006;11:25-29 Crossref
  • [36] J.B. Bartlett, A. Michael, I.A. Clarke, K. Dredge, S. Nicholson, H. Kristeleit, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer. 2004;90:955-961 Crossref
  • [37] V. Kotla, S. Goel, S. Nischal, C. Heuck, K. Vivek, B. Das, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36 Crossref
  • [38] T.A. Fehniger, S. Larson, K. Trinkaus, M.J. Siegel, A.F. Cashen, K.A. Blum, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011;118:5119-5125 Crossref
  • [39] B. Boll, P. Borchmann, M.S. Topp, M. Hanel, K.S. Reiners, A. Engert, et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol. 2010;148:480-482
  • [40] A. Tempescul, J.C. Ianotto, J.R. Eveillard, G. Guillerm, C. Berthou. ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation. Ann Hematol. 2011;90:971-973 Crossref
  • [41] J. Adams. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4:349-360 Crossref
  • [42] K.A. Blum, J.L. Johnson, D. Niedzwiecki, G.P. Canellos, B.D. Cheson, N.L. Bartlett. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma. 2007;48:1313-1319 Crossref
  • [43] A. Younes, B. Pro, L. Fayad. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood. 2006;107:1731-1732
  • [44] K.S. Reiners, A. Gossmann, E.P. von Strandmann, B. Boll, A. Engert, P. Borchmann. Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma. J Immunother. 2009;32:508-512 Crossref
  • [45] W. Rasheed, M. Bishton, R.W. Johnstone, H.M. Prince. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther. 2008;8:413-432 Crossref
  • [46] S. Kewitz, T. Bernig, M.S. Staege. Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells. Leuk Res. 2012;36:773-778 Crossref
  • [47] M.H. Kirschbaum, B.H. Goldman, J.M. Zain, J.R. Cook, L.M. Rimsza, S.J. Forman, et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma. 2012;53:259-262 Crossref
  • [48] A. Younes, A. Sureda, D. Ben-Yehuda, P.L. Zinzani, T.C. Ong, H.M. Prince, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30:2197-2203 Crossref
  • [49] M. Lemoine, E. Derenzini, D. Buglio, L.J. Medeiros, R.E. Davis, J. Zhang, et al. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood. 2012;119:4017-4025

Footnotes

a Department of Basic Medical Sciences, Neurosciences, and Sensory Organs, University of Bari Medical School, Bari, Italy

b Department of Emergency and Transplantation, Pathology Section, University of Bari Medical School, Bari, Italy

c Department of Emergency and Transplantation, Hematology Section, University of Bari Medical School, Bari, Italy

d National Cancer Institute “Giovanni Paolo II”, Bari, Italy

lowast Corresponding author at: Department of Basic Medical Sciences, Neurosciences, and Sensory Organs, University of Bari Medical School, Piazza Giulio Cesare, 11, 70124 Bari, Italy. Tel.: +39 080 5478326; fax: +39 080 5478310.